The Health Economics of INSULIN

6 Responses

1. Roman, on October 30, 2021 at 3:56 PM said:

   Expensive Insulin
   https://www.msn.com/en-us/health/medical/her-insulin-is-too-expensive-so-shes-been-forced-to-cut-doses/vi-AAQ6YWf
   Roman

   LikeLike
2. Editor-in-Chief, on January 31, 2022 at 4:05 PM said:

   Banting and Best
   https://getpocket.com/explore/item/the-discovery-of-insulin-a-story-of-monstrous-egos-and-toxic-rivalries?utm_source=pocket-newtab
   Dr. David E. Marcinko MBA

   LikeLike
3. Editor-in-Chief, on March 10, 2022 at 1:16 AM said:

   Insulin
   https://www.msn.com/en-us/news/politics/limits-on-insulin-costs-revived-in-push-for-senate-action/ar-AAUP081?li=BBnb7Kz
   Roman

   LikeLike
4. The D.E.A. ROGUE WARRIOR, on July 31, 2022 at 11:12 PM said:

   UPDATE:
   https://www.washingtonpost.com/news/magazine/wp/2019/01/07/feature/insulin-is-a-lifesaving-drug-but-it-has-become-intolerably-expensive-and-the-consequences-can-be-tragic/
   Ben

   LikeLike
5. The D.E.A. ROGUE WARRIOR, on August 7, 2022 at 6:33 PM said:

   Insulin CAP
   A proposal to cap insulin costs for people with private insurance won’t be part of the sweeping climate and health care legislation that Senate Democrats are about to pass after Republicans moved to strip it out of the bill.
   Jake

   LikeLiked by 1 person
6. Anonymous, on February 8, 2023 at 6:30 PM said:

   INSULIN LAW SUITS

   A new lawsuit targeting the price of insulin could spell trouble for the nation’s largest diabetes drug manufacturers and the companies they negotiate with for health plan rebates.

   California Attorney General Rob Bonta sued Eli Lilly, Novo Nordisk, and Sanofi—which produce more than 90% of the global insulin supply—and pharmacy benefit managers (PBMs) CVS Caremark, Express Scripts, and Optum Rx last month for allegedly using their market power to hike up the cost of insulin. The PBMs handle pharmacy benefits for about 80% of all prescription claims nationally.

   California is the latest (and largest!) state to sue drug companies and PBMs over the cost of insulin—joining lawsuits filed from May 2019 to December 2022 from the attorneys general in Kentucky, Arkansas, Mississippi, and Kansas. (Minnesota, meanwhile, defended its insulin affordability law in 2021.)

   If successful, California’s challenge could have implications that extend far beyond the borders of that state (same goes for others with pending litigation).

   Norman

   LikeLike